Mini-reviewMetronomic chemotherapy in head and neck cancer

- Over the last decades, survival in head neck cancer (HNC) has not improved.
- The role of metronomic chemotherapy (MCHT) in HNC is still debated.
- Randomized trials are limited, but results are promising.
- This analysis suggests that MCHT could offer improved outcomes in HNC.

Head neck cancer (HNC) is generally treated with a multimodality approach. Loco-regional-distant control is often worst, due to the advantage stage disease at diagnosis and the optimal treatment option remains an unresolved issue. Metronomic chemotherapy (MCHT) is an emerging therapeutic option in clinical oncology and it may prove useful in HNC patients.